WO2024059819A3 - Compositions de cannabinoïdes pour administration par inhalation - Google Patents

Compositions de cannabinoïdes pour administration par inhalation Download PDF

Info

Publication number
WO2024059819A3
WO2024059819A3 PCT/US2023/074345 US2023074345W WO2024059819A3 WO 2024059819 A3 WO2024059819 A3 WO 2024059819A3 US 2023074345 W US2023074345 W US 2023074345W WO 2024059819 A3 WO2024059819 A3 WO 2024059819A3
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoids
inhalation
delivery
compositions
preparations
Prior art date
Application number
PCT/US2023/074345
Other languages
English (en)
Other versions
WO2024059819A2 (fr
Inventor
Donald E. OWENS III
John J. KOLENG Jr.
Sawittree SAHAKIJPIJARN
Original Assignee
Tff Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tff Pharmaceuticals, Inc. filed Critical Tff Pharmaceuticals, Inc.
Publication of WO2024059819A2 publication Critical patent/WO2024059819A2/fr
Publication of WO2024059819A3 publication Critical patent/WO2024059819A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente divulgation concerne des préparations de film mince de cannabinoïdes (par exemple, du cannabidiol (CBD)) comprenant en outre un mélange stéarate de magnésium/menthol dans la préparation de poudres sèches utilisées en administration par inhalation aux et/ou à travers les poumons. Les préparations sont utiles dans le traitement de diverses maladies et troubles.
PCT/US2023/074345 2022-09-15 2023-09-15 Compositions de cannabinoïdes pour administration par inhalation WO2024059819A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263407088P 2022-09-15 2022-09-15
US63/407,088 2022-09-15

Publications (2)

Publication Number Publication Date
WO2024059819A2 WO2024059819A2 (fr) 2024-03-21
WO2024059819A3 true WO2024059819A3 (fr) 2024-05-16

Family

ID=88315858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/074345 WO2024059819A2 (fr) 2022-09-15 2023-09-15 Compositions de cannabinoïdes pour administration par inhalation

Country Status (1)

Country Link
WO (1) WO2024059819A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020222029A1 (fr) * 2019-04-30 2020-11-05 Vialpando, Llc Composition cannabinoïde et procédés de fabrication
WO2021055672A1 (fr) * 2019-09-18 2021-03-25 Board Of Regents, The University Of Texas System Compositions de cannabinoïdes pour administration par inhalation
WO2021188748A1 (fr) * 2020-03-19 2021-09-23 Tff Pharmaceuticals, Inc. Inhalation de particules séchées pour l'administration de cannabis
WO2023283592A1 (fr) * 2021-07-08 2023-01-12 484 Science Corp. Formulations pour le traitement de troubles respiratoires

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US6440101B1 (en) 2000-05-31 2002-08-27 Abbott Laboratories Syringe systems for lyophilized drugs and methods for making the same
US7959600B2 (en) 2004-12-30 2011-06-14 Byeong S. Chang Container closure delivery system
US20090208582A1 (en) 2008-02-13 2009-08-20 Board Of Regents, The University Of Texas System Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary Delivery
AU2009234598C1 (en) 2008-04-09 2012-08-23 Viromed Co., Ltd. Lyophilized DNA formulations for enhanced expression of plasmid DNA
KR101558026B1 (ko) 2008-06-13 2015-10-06 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
EP2408499B1 (fr) 2009-03-18 2014-03-05 MannKind Corporation Adaptateur d'inhalateur pour appareil à diffraction laser et procédé de mesure de la distribution granulométrique
US20170216538A1 (en) 2016-01-29 2017-08-03 Mannkind Corporation Dry Powder Inhaler

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020222029A1 (fr) * 2019-04-30 2020-11-05 Vialpando, Llc Composition cannabinoïde et procédés de fabrication
WO2021055672A1 (fr) * 2019-09-18 2021-03-25 Board Of Regents, The University Of Texas System Compositions de cannabinoïdes pour administration par inhalation
WO2021188748A1 (fr) * 2020-03-19 2021-09-23 Tff Pharmaceuticals, Inc. Inhalation de particules séchées pour l'administration de cannabis
WO2023283592A1 (fr) * 2021-07-08 2023-01-12 484 Science Corp. Formulations pour le traitement de troubles respiratoires

Also Published As

Publication number Publication date
WO2024059819A2 (fr) 2024-03-21

Similar Documents

Publication Publication Date Title
NZ548225A (en) Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
ATE377416T1 (de) Pharmazeutische formulierungen für trockenpulverinhalatoren
BRPI0508170A (pt) formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem
Yang et al. Suppression of LPS‐induced inflammation by chalcone Flavokawain A through activation of Nrf2/ARE‐mediated antioxidant genes and inhibition of ROS/NFκB signaling pathways in primary splenocytes
KR20040032851A (ko) Δ^8 테트라히드로카나비놀의 에어로졸 제형
MX2022001724A (es) Composicion farmaceutica que comprende ensifentrina.
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
WO2024059819A3 (fr) Compositions de cannabinoïdes pour administration par inhalation
EP2253312A3 (fr) Utilisation d'osmolytes obtenus à partir de bacteries extremophiles pour produire des médicaments inhalables pour la prophylaxie et le traitment de maladies pulmonaires et cardiovasculaires et un dispositif d'inhalation contenant des osmolytes comme composants actifs
Aguzzi et al. Evaluation of anti-inflammatory and immunoregulatory activities of Stimunex® and Stimunex D3® in human monocytes/macrophages stimulated with LPS or IL-4/IL-13
MX2021011491A (es) Polvos secos inhalables.
KR102482699B1 (ko) N,n''-비스-2-머캅토에틸 이소프탈아미드의 용도
US20170152285A1 (en) Extracting method of kuguacin, pharmaceutical composition comprising the kuguacin and use thereof
CN114796168A (zh) 一种羧甲司坦雾化吸入用溶液制剂及其制备方法
JPH101442A (ja) 鼻炎用点鼻薬
EP4099983A1 (fr) Composition sous forme de poudre contenant un extrait de cannabis sativa pour le traitement d'inflammations ou d'infections ou d'allergies du système respiratoire, et/ou de l'hypersécrétion de mucus, et dispositif de dosage associé
CN114344380A (zh) 一种止喘灵雾化吸入用溶液制剂及其制备方法
CN107334754B (zh) 一种清开灵雾化吸入用溶液制剂及其制备方法
WO2024104313A1 (fr) Composition pour prétraitement antiviral ou par oxydation, son procédé de préparation et son procédé d'utilisation
WO2021245654A8 (fr) Compositions comprenant de la nicotine et des anesthésiques volatils pour inhalation et leurs utilisations antivirales
WO2017147420A1 (fr) Procédés et compositions avec des composés de vitamine d pour le traitement de la fibrose kystique et de troubles respiratoires
CN109498625B (zh) 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法
WO2022081310A3 (fr) Médicaments inhalés inhibiteurs de pde-v
WO2022072864A3 (fr) Stabilisation de cannabinoïdes dans des formes posologiques solides
EP1249242B1 (fr) Composition phytothérapeutique à base des extraits hydroglycériques pour administration par aérosol